Short answer
Immunome Inc. (IMNM) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results covered quarter ended June 30, 2026.
Immunome Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Business update and financial results provided in Exhibit 99.1
- August 11, 2026 announcement marks earnings disclosure for Immunome shareholders
Item EX-99.1 · Exhibit EX-99.1
- FDA accepted varegacestat NDA; PDUFA decision target April 28, 2027, creating a defined regulatory catalyst
- Phase 3 RINGSIDE showed 84% lower progression-or-death risk and 56% objective response rate versus 9% placebo
- Cash, equivalents and marketable securities totaled $520.0M, with management projecting operational funding into 2028
- Quarterly net loss reached $73.1M as R&D increased to $59.9M and G&A to $18.3M
- IM-1617 and IM-3050 entered Phase 1, expanding clinical-stage ADC and radioligand opportunities beyond varegacestat
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Immunome Inc. 8-K filings
Get the next IMNM 8-K as it lands
Follow IMNM for push alerts, or ask the research agent what this filing means.